The first-quarter earnings season for the drug and biotech sector will be in full swing this week, with many large drugmakers ...

Shanghai-based medical device start-up United InnoMed plans to collaborate with medical institutions in Hong Kong on clinical ...

Thank you for joining us for Eli Lilly & Company's Q1 2025 earnings call ... which is a pretty serious unmet medical need. So I'm sorry to see that, but it's kind of hard to think of the incentive ...

Eli Lilly (LLY ... stock from the broader Zacks Medical sector, Zealand Pharma A/S (ZLDPF), is yet to report results for the quarter ended March 2025. This company is expected to post quarterly ...

After taking part in a landmark case against the manufacturers of the synthetic hormone DES, she represented many other ...

Creyon Bio, Inc. ("Creyon") today announced a global licensing and multi-target research collaboration with Eli Lilly and Company ("Lilly") focused on the discovery, development and commercialization ...

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

The first-quarter earnings season for the drug and biotech sector will be in full swing this week, with many large drugmakers ...

Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector ... quarter, the company delivered an earnings surprise of 5.77%. Lilly has an Earnings ESP ...

Eli Lilly and Company's stock fell over 11% after CVS ... of patients may still get Zepbound via plan-specific decisions or medical necessity appeals. We also think Lilly will respond strategically.

The S&P 500 advanced 0.6% on Thursday, May 1, securing its eighth straight winning session as strong results from Microsoft ...